I’ve been traveling in Europe, including giving a talk at the Salzburg Global Seminar on involving & informing patients in health care decisions. In that talk, I talked about promotion of a newer form of cancer radiation therapy called IMRT or intensity-modulated radiation therapy.
So I want to point out that, while I’ve been away, the Wall Street Journal published an important piece on this very topic, under the headline, “A Device to Kill Cancer, Lift Revenue.”
Opinions on other issues in news, journals, PR, advertising, marketing
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Gregory D. Pawelski
December 16, 2010 at 2:47 pmI was well aware that myelodysplastic syndrome (MDS) can be caused by treatment with chemotherapy. I was rudely reminded three years ago that radiation therapy can cause it too (treatment-related MDS or secondary MDS). Treatment-related MDS is often more severe and diffult to treat than de novo MDS (unknown changes to the bone marrow). I lost my brother-in-law (my wife’s brother) to MDS after he received permanent seed implants for “early” prostate cancer treatment (he was in his ’70s). Urologists can hardly hold themselves back and are out with all sorts of treatments. Sometimes, while a life may be saved, a life may be taken. I have experienced for the second time in my life, the issue. It does happen, but no one emphasizes that point.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like